Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05047991
Other study ID # HE072-CSP-004
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date October 2021
Est. completion date November 2024

Study information

Verified date September 2021
Source CSPC Ouyi Pharmaceutical Co., Ltd.
Contact Jihui Hao, Ph.D
Phone 86-18622221120
Email haojihui@tjmuch.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, randomized, open-lable, parallel-controlled phase II study of irinotecan liposome injection-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma. The purpose of this study is to evaluate the differences of safety and efficacy of irinotecan liposome injection-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma.


Description:

This is a multicentre randomized, open-label, parallel-controlled, phase II study to evaluate the efficacy and safety of irinotecan liposome injection-containing regimens. Eligible patients will be randomly divided into two cohorts at a ratio of 2:1. The patients in cohort 1 (the experimental group) will receive irinotecan liposome injection combined with 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin.The patients in cohort 2 (the control group) will receive nab-paclitaxel plus gemcitabine.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 153
Est. completion date November 2024
Est. primary completion date November 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Age 18 to 70 years old (inclusive), regardless of gender; 2. Histologically or cytologically confirmed unresectable, locally advanced, or metastatic pancreatic adenocarcinoma; 3. At least one measurable lesion according to RECIST 1.1. 4. No prior systemic anti-tumor therapy, except those with disease progression more than 6 months after adjuvant therapy or neoadjuvant therapy; 5. Patients with prior local treatment (radical radiotherapy or radical chemoradiotherapy, etc.) may be enrolled provided that the local treatment does not involve the target lesion, or the target lesion is within the treatment area, but the size has increased more than 20% since the post-treatment evaluation, and also must be completed at least 4 weeks before the first administration of the study drug, palliative decompensated radiotherapy (such as bone metastases) must be completed at least 2 weeks before the first administration of the study drug; 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1; 7. Life expectancy >3 months; 8. Adverse reactions must recover to grade 1 or baseline according to CTCAE 5.0 (except for toxicity such as alopecia, grade 2 or less sensory neuropathy, etc., which have been judged no safety risk by investigators). 9. Patients should not receive cell growth factors or blood and platelet transfusion within 7 days before the initiate administration of study drug, and laboratory test must meet the following criteria: neutrophile count =1.5×10^9/L; platelet count =100×10^9/L; hemoglobin =90 g/L or =5.6 mmol/L; serum creatinine =1×ULN or creatinine clearance rate must be = 50 mL/min when serum creatinine >1.0×ULN; total bilirubin =1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5×ULN or =5×ULN if intrahepatic lesions exist; Albumin =3 g/dL. 10. Activated Partial Thromboplastin Time (APTT), International Normalized Ratio (INR) and prothrombin time (PT) =1.5 × ULN for patients not receiving therapeutic anticoagulation. 11. According to the related guidelines, patients with HBV DNA or HBsAg and/or anti-HBC positive must receive prophylactic treatment (at least one week before the initial administration of the study drug) and take antiviral drugs in stable dose (e.g., entecavir, tenofovir, or lamivudine; No adefovir or interferon are allowed) at study entry with planned monitoring and management, including baseline HBV DNA levels. Patient receiving active hepatitis C virus (HCV) treatment must use astable dose of drugs at study entry and be subject to planned monitoring and management according to antiviral drug guidelines; 12. Female patients with reproductive potential must agree to use adequate contraception from the signing of informed consent to at least 6 months after the study completion and have a negative serum pregnancy test within 3 days before enrollment, and must be non-lactating. Male patients must agree to use medically approved contraception during the study period and for 6 months after the study completion; 13. Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: 1. Patients with acinar cell carcinoma, pancreatoblastoma, solid pseudopapillary tumor and pancreatic neuroendocrine tumor; 2. Patients with definitive diagnosis of CNS metastasis; 3. Patients with hepatic encephalopathy at screening; 4. Patients with clinically symptomatic ascites requiring puncture or drainage or who have received ascites drainage within the past 3 months, except for those with only a small amount of ascites on imaging but no clinical symptoms; 5. Uncontrolled third lacunar effusion other than ascites (e.g., large pleural or pericardial effusion) within 4 weeks before the first administration of the test drug; 6. Previous malignancies in the past five years (except radically resected and non-recurring basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, local prostate carcinoma, carcinoma in situ of cervical, or other carcinoma in situ); 7. Patients with partial or complete biliary obstruction who has not relieved by active treatment; 8. History of serious cardiovascular disease, including but not limited to: 1) Acute myocardial infarction, unstable angina pectoris, coronary angioplasty, stroke, severe pulmonary embolism; 2) New York Heart Association class grade III or IV congestive heart failure or left ventricular ejection fraction (LVEF) < 50%; 3) Poorly controlled hypertension (systolic blood pressure = 150 mmHg and/or diastolic blood pressure= 95 mmHg) with optimal treatment; 4) Ventricular arrhythmia; 5) Patients with prolonged QT/QTc interval in baseline electrocardiogram (ECG) (QTcF > 480 ms, Fridericia formula: QTcF = QT/(RR^0.33), RR = 60/heart rate); 6) Patients with clinically significant abnormal electrocardiogram (ECG) according to the investigator's assessment. 9.Patients with uncontrolled active bleeding. 10.Patients with known interstitial lung disease; 11.Patients with known peripheral neuropathy (CTCAE grade 3 or 4); 12.Patients with severe lung, liver, kidney, endocrine, immune system, skin or musculoskeletal diseases within 3 months prior to the first dose and who are not suitable for enrollment in the opinion of the investigator; 13.Patients who are at risk of active infection or have active infection that may affect the results of the study (such as severe pneumonia requiring hospitalization, bacteremia, acute bacterial infection, infectious complications, tuberculosis, active HIV infection, etc.) or who, in the judgment of the investigator, are not suitable for participation in this clinical trial. Active hepatitis B virus is defined as HBV DNA=10^4 copies or = 2000 IU/mL; active hepatitis C virus or active HIV infection is defined as HCV-RNA positive; 14.Gastrointestinal diseases of clinical significance, such as bleeding, inflammation, obstruction, >grade 1 diarrhea, malabsorption syndrome, diseases significantly affecting gastrointestinal function, gastric or small bowel resection, etc; 15.Patients with known to have dihydropyrimidine dehydrogenase (low activity) or deficiency; 16.Patients with definite Gilbert syndrome; 17.History of explicit neurological or psychiatric disorders, including epilepsy or dementia; 18.Patients with known alcohol or drug dependence. 19.Patients who have concomitant use of strong CYP3A4 inducers within 2 weeks prior to the first dose, or strong CYP3A4 inhibitors or strong UGT1A1 inhibitors within 1 week prior to the first dose; 20.Patients who have required systemic glucocorticoids (prednisone >10 mg/day or equivalent dose of the similar drugs) or other immunosuppressive agents within 14 days before the first dose of the study drug. Except for treatment with local, ocular, intra-articular, intranasal, and inhaled glucocorticoids in the absence of active autoimmune disease, short-term preventive treatment with glucocorticoids (e.g., prevention of contrast allergy); 21.Patients who have major organ surgery (except for needle biopsy, central venous catheterization, port-cath, stenting to relieve biliary obstruction, and percutaneous hepatic biliary drainage, cholecystostomy) or selective operation plan were performed within 4 weeks before the first dose of the study drug; 22.Patients with known allergy to irinotecan liposome injection, other liposome products, oxaliplatin, 5-fluorouracil, leucovorin, Nab-paclitaxel, other albumin products, gemcitabine or any of the ingredients in the above products.; 23. Patients who are not suitable for this study as determined by the investigator.

Study Design


Intervention

Drug:
Irinotecan Liposome Injection
Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle
Fluorouracil
5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
Leucovorin
Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
Oxaliplatin
Oxaliplatin, intravenously, over 2 h on day 1 and day 15 of every 28-day cycle
Nab paclitaxel
Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle
Gemcitabine
Gemcitabine, intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
CSPC Ouyi Pharmaceutical Co., Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-Free Survival (PFS) Time from date of the first dose to date of recorded disease progression or death, whichever occurs first. Up to twelve months after the last patient's first administration
Secondary Objective Response Rate (ORR) The percentage of patients who achieve a complete response (CR) or partial response (PR) based on the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) Up to twelve months after the last patient's first administration
Secondary Overall survival (OS) Time from date of the first dose to date of death from any cause. Up to twelve months after the last patient's first administration
Secondary Disease Control Rate (DCR) The percentage of patients who achieve a CR, PR or stable disease (SD) based on the RECIST 1.1. Up to twelve months after the last patient's first administration
Secondary Duration of Response (DOR) Time from first documented response (CR or PR whichever occurs first, based on investigator's assessment per RECIST 1.1) to date of disease progression or death due to any cause, whichever occurs first. Up to twelve months after the last patient's first administration
Secondary Incidence of treatment-related adverse events (AEs) and serious adverse events (SAEs) The AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0. Up to twelve months after the last patient's first administration
Secondary Peak Plasma Concentration Cmax Day 0 to Day 7 of circle 1
Secondary Area under the plasma concentration versus time curve AUC Day 0 to Day 7 of circle 1
Secondary UGT1A1 UGT1A1 gene polymorphism Within 3 days before the first dose
See also
  Status Clinical Trial Phase
Completed NCT02128100 - Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer Phase 2
Completed NCT03590275 - Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX
Recruiting NCT05265663 - Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients N/A
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Recruiting NCT06160323 - Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer N/A
Active, not recruiting NCT04156087 - Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT06387368 - Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer Phase 4
Active, not recruiting NCT03941093 - Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer Phase 3
Recruiting NCT03165591 - Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT05549414 - Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System N/A
Recruiting NCT06388967 - Pancreatic Cancer Detection Consortium
Not yet recruiting NCT06375967 - EUS-Gallbladder vs CDS as First Line in MBDO- Palliative (CARPEGIEM Trial) N/A
Withdrawn NCT04852367 - PanDox: Targeted Doxorubicin in Pancreatic Tumours Phase 1
Recruiting NCT03977233 - Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer Phase 2
Recruiting NCT03964064 - I125 Seed Implantation vs Stereotactic Radiotherapy for Pancreatic Cancer N/A
Not yet recruiting NCT06361030 - Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT05424159 - Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer N/A
Terminated NCT01887041 - Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer Phase 4
Recruiting NCT06453590 - Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents N/A
Active, not recruiting NCT03984214 - Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer Phase 3